Prostate cancer is the most frequent malignant neoplasm in men and the second most common cancer death among American men. Screening for prostate cancer is not recommended for men under 50 (unless the patient has a first-degree relative diagnosed with prostate cancer younger than 65 years), for men over 65 with a life expectancy of less than 10 years, or in men over 75. Screening for prostate cancer should include testing for prostate specific antigen (PSA). Digital rectal exam (DRE) may also be used as a complementary baseline test.
Refer to ARUP Laboratories’ test offerings below.
ARUP Laboratory Tests
Quantitative Electrochemiluminescent Immunoassay